Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165469 | 0.87 | ALDH1A1 (0.32) | ALDH1A1TSHRTDP1 | |
| SCHEMBL14616012 | 0.86 | KIF11 (0.31) | — | |
| SCHEMBL4974374 | 0.85 | — | — | |
| SCHEMBL19003665 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1MCHR1 | |
| SCHEMBL19404364 | 0.84 | DNM1 (0.31) | ALDH1A1TSHRTDP1 | |
| SCHEMBL3175803 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL15270046 | 0.83 | — | — | |
| SCHEMBL22301042 | 0.83 | — | — | |
| SCHEMBL22857442 | 0.83 | — | — | |
| SCHEMBL17994099 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024143038-A1 | POLYOL-CONTAINING COMPOSITION, AND POLYURETHANE AND WATER-BASED POLYURETHANE MADE THEREFROM | 旭化成株式会社 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024044327-A1 | DHNT MONOMERS AND POLYMER DYES WITH MODIFIED PHOTOPHYSICAL PROPERTIES | BECKMAN COULTER, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023244517-A1 | INTERLEUKIN-2 PRODRUGS | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11730826-B2 | Amphiphilic nanoparticles for delivery of CRISPR based therapy | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023116702-A1 | PH-SENSITIVE MEMBRANE-BREAKING POLYPEPTIDE AND USE THEREOF | 华南理工大学 | 2023-06-29 | — | — | WO | disclosed |
| US-20230130084-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-04-27 | — | — | US | disclosed |
| US-20220211868-A1 | NANOPARTICLES COMPRISING NON-CLASSICAL MHC AND USES THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2022-07-07 | — | — | US | disclosed |
| US-20220193210-A1 | THERAPEUTICS FOR AUTOIMMUNE KIDNEY DISEASE: SYNTHETIC ANTIGENS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2022-06-23 | — | — | US | disclosed |
| US-11338024-B2 | Methods and compositions for sustained immunotherapy | UTI LIMITED PARTNERSHIP (CA) | 2022-05-24 | — | — | US | disclosed |
| US-20220125752-A1 | LEVODOPA DERIVATIVE AND USE THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20120101037-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE ANALOGS | HOFFMANN-LA ROCHE INC. | 2012-04-26 | — | — | US | disclosed |
| US-20120094955-A1 | METHOD OF DISSOLVING AN OXIDIZED POLYSACCHARIDE IN AN AQUEOUS SOLUTION | ACTAMAX SURGICAL MATERIALS LLC (US) | 2012-04-19 | — | — | US | disclosed |
| EP-1962959-B1 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110284458-A1 | COMPOSITE MEMBRANE WITH COATING COMPRISING POLYALKYLENE OXIDE AND BIGUANIDE-TYPE COMPOUNDS | DOW GLOBAL TECHNOLOGIES LLC | 2011-11-24 | — | — | US | disclosed |
| WO-2011113065-A2 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110142886-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010070132-A1 | THIOIC ACIDS AS BUILDING BLOCK FOR POLYTHIOESTERS | DSM IP ASSETS B.V. (NL) | 2010-06-24 | — | — | WO | disclosed |
| US-20100112026-A1 | SURFACES, METHODS AND DEVICES EMPLOYING CELL ROLLING | MASSACHUSETTS INSTITUTE TO TECHNOLOGY (US) | 2010-05-06 | — | — | US | disclosed |
| US-7276475-B2 | Remodeling and glycoconjugation of peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2007065808-A2 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142886-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | PARN, PUF60, PARG | ALDH1A1 4268/4885TSHR 3477/4885TDP1 271/4885 |
| US-11730826-B2 | Amphiphilic nanoparticles for delivery of CRISPR based therapy | ABCB4, ABCB1, ZFR | ALDH1A1 2916/4885TSHR 4119/4885TDP1 1596/4885 |
| US-20120094955-A1 | METHOD OF DISSOLVING AN OXIDIZED POLYSACCHARIDE IN AN AQUEOUS SOLUTION | SI, OGFOD1, OSTC | ALDH1A1 777/4885TSHR 3622/4885TDP1 2933/4885 |
| US-20220193210-A1 | THERAPEUTICS FOR AUTOIMMUNE KIDNEY DISEASE: SYNTHETIC ANTIGENS | SSB, HAVCR2, CD47 | ALDH1A1 3142/4885TSHR 460/4885TDP1 4872/4885 |
| US-20120101037-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE ANALOGS | GIPR, GPR119, GLP1R | ALDH1A1 4569/4885TSHR 102/4885TDP1 4725/4885 |
| US-11338024-B2 | Methods and compositions for sustained immunotherapy | CD47, TFRC, ICOS | ALDH1A1 3596/4885TSHR 1032/4885TDP1 3950/4885 |
| US-20220125752-A1 | LEVODOPA DERIVATIVE AND USE THEREOF | PARK7, COMT, SNCA | ALDH1A1 744/4885TSHR 2743/4885TDP1 1091/4885 |
| US-20220211868-A1 | NANOPARTICLES COMPRISING NON-CLASSICAL MHC AND USES THEREOF | MICA, CD74, HLA-C | ALDH1A1 1091/4885TSHR 3506/4885TDP1 4811/4885 |
| US-20230130084-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | ALG1, CD44, CD47 | ALDH1A1 511/4885TSHR 4751/4885TDP1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.